{
    "clinical_study": {
        "@rank": "85836", 
        "arm_group": [
            {
                "arm_group_label": "Ruxolitinib plus Pemetrexed/Cisplatin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo plus Pemetrexed/Cisplatin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if ruxolitinib, in combination with\n      Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of\n      nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent."
        }, 
        "brief_title": "Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study consists of an open-label, safety run-in (consisting of 1 to 4 cohorts of 9\n      subjects each), to confirm the safety of ruxolitinib in combination with\n      pemetrexed/cisplatin in subjects with nonsquamous non-small cell lung cancer (NSCLC) that is\n      Stage IIIB, Stage IV, or recurrent. Subjects in the safety run-in will receive open-label\n      ruxolitinib and pemetrexed and cisplatin.\n\n      In the second part of the study, subjects will be enrolled and randomized  to receive\n      pemetrexed and cisplatin (open-label) and either ruxolitinib or placebo in a blinded manner.\n      The dose of ruxolitinib administered will be determined from the data produced in the safety\n      run-in phase.\n\n      Treatment will consist of repeating 21-day cycles. Subjects will receive infusions of\n      pemetrexed and cisplatin on Day 1 of each cycle and ruxolitinib/placebo will be\n      self-administered during the entire cycle. Maintenance therapy with ruxolitinib or placebo\n      in combination with pemetrexed, based on the original treatment assignment, will be allowed\n      for subjects eligible for maintenance therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is\n             Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation,\n             surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant\n             chemotherapy).\n\n          -  Radiographically measurable or evaluable disease.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Tumor without a driver mutation (eg, epidermal growth factor receptor mutation\n             positive or anaplastic lymphoma kinase fusion oncogene positive).\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\n          -  Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified\n             laboratory parameters at the screening visit\n\n        Exclusion Criteria:\n\n          -  Squamous or mixed histology (eg, adenosquamous) NSCLC\n\n          -  Previous systemic therapy for advanced or metastatic disease.\n\n          -  Known active central nervous system (CNS) metastases.\n\n          -  Current or previous other malignancy within 2 years of study entry, except cured\n             basal or squamous cell skin cancer, superficial bladder cancer, prostate\n             intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or\n             indolent malignancy without sponsor approval.\n\n          -  Current uncontrolled cardiac disease such as angina or myocardial infarction,\n             congestive heart failure including New York Heart Association functional\n             classification of 3, or arrhythmia requiring treatment.\n\n          -  Uncontrolled concomitant medical conditions, including, but not limited to, renal,\n             hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral,\n             or psychiatric diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "156", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119650", 
            "org_study_id": "INCB 18424-266"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ruxolitinib plus Pemetrexed/Cisplatin", 
                "description": "5 mg tablets to be administered by mouth at dose selected from safety run-in phase\n(Ruxolitinib 15mg BID or Ruxolitinib 10mg BID)", 
                "intervention_name": "Ruxolitinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Jakafi \u00ae", 
                    "Jakavi \u00ae"
                ]
            }, 
            {
                "arm_group_label": "Placebo plus Pemetrexed/Cisplatin", 
                "description": "5 mg matching placebo tablets to be administered by mouth", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ruxolitinib plus Pemetrexed/Cisplatin", 
                    "Placebo plus Pemetrexed/Cisplatin"
                ], 
                "description": "500 mg/m^2 administered as an intravenous infusion over 10 minutes", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug", 
                "other_name": "Alimta\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Ruxolitinib plus Pemetrexed/Cisplatin", 
                    "Placebo plus Pemetrexed/Cisplatin"
                ], 
                "description": "75 mg/m^2 infused over 2 hours beginning 30 \u00b1 5 minutes after the end of the pemetrexed infusion", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Non small cell lung cancer", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwich", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southington", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Joilet", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reno", 
                        "country": "United States", 
                        "state": "Nevada"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount Kisco", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ogden", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leesburg", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kennewick", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent", 
        "overall_contact": {
            "last_name": "Incyte Corporation Call Center", 
            "phone": "1-855-463-3463"
        }, 
        "overall_official": {
            "affiliation": "Incyte Corporation", 
            "last_name": "Gerard T Kennealey, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Subjects will receive infusions of pemetrexed and cisplatin on Day1 of Cycle 1, and begin dosing with ruxolitinib, twice daily (BID). The safety and tolerability of the regimen will be assessed during the first 21 days of therapy.", 
                "measure": "Part 1: Determination of the dose of ruxolitinib that is safe and tolerable in combination with pemetrexed/cisplatin as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Day 21"
            }, 
            {
                "measure": "Part 2: Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Randomization until death due to any cause.  Approximately 24 months."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119650"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST)  v1.1, or death due to any cause if sooner.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Randomization to disease progression, or death due to any cause if sooner.  Approximately 24 months."
            }, 
            {
                "description": "Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment", 
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study.  Approximately 24 months."
            }, 
            {
                "description": "Duration of response determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline through end of study.  Approximately 24 months."
            }, 
            {
                "measure": "Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through approximately 30 days post treatment discontinuation.  Assessed after approximately 24 months."
            }
        ], 
        "source": "Incyte Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}